Mary Szela Biography and Net Worth

Chief Executive Officer, President and Director of TriSalus Life Sciences

Mary Szela has nearly 35 years of experience driving growth and creating value for patients and investors in both the commercial and clinical pharmaceutical arenas.

Mary has served as CEO and President of TriSalus Life Sciences since January 2018. Prior to joining TriSalus, Mary served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she led the company through regulatory compliance and legal difficulties, ultimately orchestrating a successful merger and expansion of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company’s revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus).

Previously, Mary held progressive leadership roles at Abbott Laboratories including President of the company’s $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Senior Vice President for global strategic marketing and services.

Mary currently serves as a member of the Board of Directors for Kura Oncology, Prometheus Biosciences, Omega Therapeutics and Senda Biosciences. She received both her B.S. in Nursing and her MBA from the University of Illinois at Chicago.

What is Mary T. Szela's net worth?: The estimated net worth of Mary T. Szela is at least $4.32 million as of May 15th, 2026. Ms. Szela owns 1,065,215 shares of TriSalus Life Sciences stock worth more than $4,319,447 as of June 22nd. This net worth approximation does not reflect any other assets that Ms. Szela may own. Learn More about Mary T. Szela's net worth.
How do I contact Mary T. Szela?: The corporate mailing address for Ms. Szela and other TriSalus Life Sciences executives is 6272 West 91st Avenue, Westminster, CO 80031, United States. TriSalus Life Sciences can also be reached via phone at 888-321-5212 and via email at [email protected]. Learn More on Mary T. Szela's contact information.
Has Mary T. Szela been buying or selling shares of TriSalus Life Sciences?: During the last ninety days, Mary T. Szela has bought $102,776.38 in TriSalus Life Sciences stock. Most recently, on Friday, May 15th, Mary T. Szela bought 39,682 shares of TriSalus Life Sciences stock. The stock was acquired at an average cost of $2.59 per share, with a total value of $102,776.38. Following the completion of the transaction, the chief executive officer now directly owns 1,065,215 shares of the company's stock, valued at $2,758,906.85. Learn More on Mary T. Szela's trading history.
Who are TriSalus Life Sciences' active insiders?: TriSalus Life Sciences' insider roster includes Bryan Cox (Chief of Research), Gary Gordon (Director), George Martin (Director), and Mary Szela (Chief Executive Officer, President and Director). Learn More on TriSalus Life Sciences' active insiders.
Are insiders buying or selling shares of TriSalus Life Sciences?: During the last twelve months, TriSalus Life Sciences insiders bought shares 5 times. They purchased a total of 719,682 shares worth more than $1,804,176.38. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 30,150 shares worth more than $119,849.35. The most recent insider tranaction occured on May, 15th when Director Mats Wahlstrom bought 60,000 shares worth more than $151,800.00. Insiders at TriSalus Life Sciences own 16.3% of the company. Learn More about insider trades at TriSalus Life Sciences.
Information on this page was last updated on 5/15/2026.

Mary T. Szela Insider Trading History at TriSalus Life Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/15/2026	Buy	39,682	$2.59	$102,776.38	1,065,215
3/17/2026	Sell	15,944	$3.85	$61,384.40	752,987
3/11/2026	Sell	4,358	$4.13	$17,998.54	768,931
1/29/2025	Buy	5,030	$5.03	$25,300.90	439,249
1/27/2025	Buy	4,826	$5.42	$26,156.92	429,503
9/12/2024	Buy	7,520	$5.20	$39,104.00	377,382
9/10/2024	Buy	5,000	$4.97	$24,850.00	369,862

Mary T. Szela Buying and Selling Activity at TriSalus Life Sciences

TriSalus Life Sciences Company Overview

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Today's Range

Now: $4.13

$3.95

$4.16

50 Day Range

MA: $3.87

$2.52

$4.65

2 Week Range

Now: $4.13

$2.20

$7.95

Volume

102,456 shs

Average Volume

294,971 shs

Market Capitalization

$253.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49